| FDA Strengthens Kidney Risk Warning for Reclast - Medscape |
|
|
Medscape September 1, 2011 — Zoledronic acid (Reclast, Novartis Pharmaceuticals), an injectable bisphosphonate used to prevent and treat osteoporosis, is now contraindicated for patients with creatinine clearance below 35 mL/min or evidence of acute renal ... Osteoporosis- Is Treatment More Dangerous Than the Disease? InjuryBoard.com Reclast (zoledronic acid): Drug Safety Communication - New Contraindication |